CBPD‑409, an Oral CBP/p300 Degrader for Advanced Prostate Cancer
CBPD‑409 is an experimental, oral medicine designed to remove two helper proteins, CBP and p300, that prostate tumors use to turn cancer‑driving genes on. These proteins partner with the androgen receptor (AR), the key signal that fuels most prostate cancers, especially in the advanced, treatment‑resistant setting. By tagging CBP and p300 for destruction, a strategy […]
